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A phase I dose escalation study of intra-tumoral LTX-315 as 
monotherapy or in combination with either ipilimumab or 
pembrolizumab in patients with transdermally accessible 
tumors (NCT01986426) 
 
This Phase I clinical study is evaluating the safety and tolerability of 
intra-tumoral doses of LTX-315 in patients with advanced/metastatic 
solid tumors. Intratumoral administration results in growth 
inhibition, complete regression and long lasting tumor specific 
immune responses in multiple pre-clinical tumor models. LTX-315 
treatment results in increased CD8+ T cell infiltration, increased 
CD8+ T cell/Treg ratio and enhanced T cell clonality. 
The oncolytic effect of LTX-315 involves immunogenic cell death as 
shown by disintegration of cytosolic organelles with subsequent 
release of DAMPs (Damage-Associated Molecular Pattern molecules) 
such as ATP, cytochrome C and HMGB1. Multi-domain proteins from 
the BCL-2 family seem to be partially involved in LTX-315 mediated 
killing. The membranolytic effect of LTX-315 also facilitates effective 
release of tumor antigens. In preclinical tumor models, combination 
of LTX-315 and immune checkpoint inhibitors demonstrates 
significant synergy. 
In this phase I study a recommended Phase II dose as monotherapy 
and in combination with immune checkpoint inhibitors will be 
determined. Post-treatment biopsies are also being collected to 
assess changes in the tumor microenvironment resulting from LTX-
315 treatment. 
Patients are being recruited to one of 4 arms. Arm A: LTX-315 
monotherapy single tumor lesion treatment; Arm B: LTX-315 
monotherapy single or multiple lesion treatment; Arm C: LTX-315 
and ipilimumab in patients with unresectable/metastatic malignant 
melanoma previously treated with an anti-PD-1 antibody; Arm D: 
LTX-315 and pembrolizumab in patients with triple negative breast 
cancer. Patients are receiving LTX-315 in transdermally accessible 
lesions on days 1, 2, 8, 9, 15 and 16. Ipilimumab and pembrolizumab 
are administered at standard dose and schedule. As of January 2017, 
28 of 60 planned patients have been recruited. Immune responses 
are assessed by analysis of T lymphocyte subsets in (peripheral 
blood) and in tumor tissue. In Arm B PD-L1 expression is assessed in 
bystander (non-injected) tumor biopsies. Anti-tumor activity is 
assessed by the immune-related response criteria (irRC) for 
measureable lesions (irCR, irPR, overall response duration, 
progression free survival (PFS), time to response and disease control 
rate (irPR, irCR and stable disease (irSD)). 
